PA
MRTX

Profund Advisors’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Profund Advisors’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-25,078
Closed -$1.47M – 1210
2023
Q4 		$1.47M Sell
25,078
-15,961
-39% -$897K 0.06% 249
2023
Q3 		$1.79M Buy
41,039
+2,205
+6% +$78.7K 0.1% 161
2023
Q2 		$1.4M Buy
38,834
+7,307
+23% +$301K 0.08% 228
2023
Q1 		$1.17M Buy
31,527
+25,747
+445% +$1.16M 0.07% 264
2022
Q4 		$262K Buy
5,780
+323
+6% +$20.9K 0.02% 735
2022
Q3 		$381K Sell
5,457
-254
-4% -$18.8K 0.03% 478
2022
Q2 		$383K Sell
5,711
-479
-8% -$30.5K 0.02% 517
2022
Q1 		$509K Sell
6,190
-626
-9% -$64K 0.02% 564
2021
Q4 		$1M Sell
6,816
-634
-9% -$98.4K 0.03% 332
2021
Q3 		$1.32M Buy
+7,450
New +$1.2M 0.04% 287
2021
Q2 		– Sell
-1,308
Closed -$224K – 1439
2021
Q1 		$224K Buy
1,308
+396
+43% +$78.4K 0.01% 1196
2020
Q4 		$200K Buy
+912
New +$197K 0.01% 1112

Other funds holding MRTX

S
Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Profund Advisors's MRTX Position: Q1 2024 in Review

Profund Advisors sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 25,078 shares — an estimated $1.47M sold.

Profund Advisors first reported a position in MRTX in Q4 2020 and held it in 12 quarters. The position peaked at $1.79M in Q3 2023. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.

  • Profund Advisors reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Profund Advisors sold 25,078 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $1.47M.
  • Profund Advisors first reported a position in Mirati Therapeutics, Inc. Common Stock in Q4 2020 and held it in 12 quarters.
  • Profund Advisors's Mirati Therapeutics, Inc. Common Stock position peaked at $1.79M in Q3 2023.
  • 2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Profund Advisors's 13F filing for Q1 2024, filed 8 May 2024.